The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

9 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors.EBI
Beijing Institute of Pharmacology and Toxicology
The green tea polyphenol (2)-epigallocatechin-3-gallate (EGCG) is not aß-secretase inhibitor.EBI
Beijing Institute of Pharmacology and Toxicology
Synthesis of a series of novel 2,4,5-trisubstituted selenazole compounds as potential PLTP inhibitors.EBI
Beijing Institute of Pharmacology and Toxicology
Discovery and pharmacological characterization of a novel benzimidazole TRPV4 antagonist with cyanocyclobutyl moiety.EBI
Beijing Institute of Pharmacology and Toxicology
Identification of novel influenza polymerase PB2 inhibitors using virtual screening approach and molecular dynamics simulation analysis of active compounds.EBI
Beijing Institute of Pharmacology and Toxicology
Discovery of highly potent and selective EGFREBI
Beijing Institute of Pharmacology and Toxicology
A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region.EBI
Beijing Institute of Pharmacology and Toxicology
Design, synthesis, and activity evaluation of novel erythropoietin mimetic peptides.EBI
Beijing Institute of Pharmacology and Toxicology
De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.EBI
Beijing Institute of Pharmacology and Toxicology